临床局限性前列腺癌的延迟治疗

Deferred treatment in clinically localised prostatic carcinoma.

作者信息

Adolfsson J, Carstensen J, Löwhagen T

机构信息

Department of Urology, Karolinska Hospital, Stockholm, Sweden.

出版信息

Br J Urol. 1992 Feb;69(2):183-7. doi: 10.1111/j.1464-410x.1992.tb15493.x.

DOI:10.1111/j.1464-410x.1992.tb15493.x

PMID:1537031

Abstract

A series of 122 patients with a cytological diagnosis of well or moderately differentiated and clinically localised (T1-2) prostatic carcinoma were followed up without any initial anti-tumour therapy. The median observation time was 91 months. During follow-up the local tumour progressed to stage T3 in 67 patients (55%) and distant metastases developed in 17 (14%); 47 patients died (38%), 9 of them (7%) from prostatic carcinoma. The risk of dying from prostatic carcinoma was 1% after 5 years and 16% after 10 years for patients not dying from other causes.

摘要

122例经细胞学诊断为高分化或中分化且临床局限（T1-2）前列腺癌的患者在未接受任何初始抗肿瘤治疗的情况下接受随访。中位观察时间为91个月。随访期间，67例患者（55%）局部肿瘤进展至T3期，17例（14%）出现远处转移；47例患者死亡（38%），其中9例（7%）死于前列腺癌。未因其他原因死亡的患者5年后死于前列腺癌的风险为1%，10年后为16%。